Literature DB >> 14567034

Intraperitoneal taxanes.

Faheez Mohamed1, Paul H Sugarbaker.   

Abstract

The taxanes appear to be promising agents for intraperitoneal use. Paclitaxel is currently undergoing Phase III investigation for the treatment of ovarian cancer. Docetaxel requires further Phase II study, but its impressive activity with systemic administration may be optimized with intraperitoneal administration for the treatment of peritoneal surface malignancy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14567034     DOI： 10.1016/s1055-3207(03)00038-3

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  14 in total

Review 1.  Peritoneal Metastases from Gastrointestinal Cancer.

Authors:  Paul H Sugarbaker
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

2.  Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review.

Authors:  Paul H Sugarbaker
Journal:  Indian J Surg Oncol       Date:  2019-01-03

Review 3.  Clinical pharmacokinetics of docetaxel : recent developments.

Authors:  Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects.

Authors:  Paul H Sugarbaker
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 5.  Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens.

Authors:  Andreas Brandl; Aruna Prabhu
Journal:  J Gastrointest Oncol       Date:  2021-04

6.  Hyperthermic intraperitoneal chemotherapy: Rationale and technique.

Authors:  Santiago González-Moreno; Luis A González-Bayón; Gloria Ortega-Pérez
Journal:  World J Gastrointest Oncol       Date:  2010-02-15

Review 7.  Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.

Authors:  Federico Coccolini; Paola Fugazzola; Giulia Montori; Luca Ansaloni; Massimo Chiarugi
Journal:  J Gastrointest Oncol       Date:  2021-04

8.  Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.

Authors:  Hyungwoo Cho; Min-Hee Ryu; Kyu-Pyo Kim; Baek-Yeol Ryoo; Sook Ryun Park; Bum Soo Kim; In-Seob Lee; Hee-Sung Kim; Moon-Won Yoo; Jeong Hwan Yook; Seong Tae Oh; Byung Sik Kim; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2017-03-16       Impact factor: 7.370

Review 9.  Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals.

Authors:  F C Muñoz-Casares; S Rufián; M J Rubio; E Lizárraga; C Díaz-Iglesias; E Aranda; R Ciria; J Muntané; P Barrios; J Torres-Melero; S González-Moreno; L González-Bayón; B Camps; P Bretcha; J Farré; G Ortega-Pérez; A Gómez-Portilla
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

10.  Disposition kinetics of taxanes in peritoneal dissemination.

Authors:  Ken'ichi Miyamoto; Tsutomu Shimada; Kazuki Sawamoto; Yoshimichi Sai; Yutaka Yonemura
Journal:  Gastroenterol Res Pract       Date:  2012-05-16       Impact factor: 2.260
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.